Objectives The hepatotoxicity of irinotecan has been widely implicated in the treatment of
multiple solid tumours. However, there are few studies on the influencing factors of …

Gemcitabine is one of the standard treatments for locally advanced pancreatic cancer.
Recent studies on metastatic pancreatic cancer have shown that combination chemotherapy …

Abstract Lessons Learned The triple combination chemotherapy of SOXIRI (S‐
1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma …

Introducción: el cáncer de páncreas se caracteriza por su agresividad biológica, mal
pronóstico oncológico y diagnóstico tardío. La mayoría con baja tasa de resecabilidad (10 …

Background This phase 1b trial evaluated the toxicity and efficacy of S-1, irinotecan, and
oxaliplatin combination therapy (S-IROX) as first-line chemotherapy in patients with …

The platinum-based chemotherapy regimen FOLFIRINOX (leucovorin, fluorouracil,
irinotecan, and oxaliplatin) is currently used as a standard treatment for patients with …

Background FOLFIRINOX (FFX) and gemcitabine (GEM) plus nab-paclitaxel (GnP) have
recently been available for treating pancreatic ductal adenocarcinoma (PDAC). We …

Irinotecan‐induced hepatotoxicity can cause severe clinical complications in patients;
however, the underlying mechanism and factors affecting hepatotoxicity have rarely been …

Background/objectives Pancreatic adenosquamous carcinoma (PASC) is a rare variant of
pancreatic ductal adenocarcinoma (PDAC). The usual treatment for metastatic or recurrent …

Abstract Background This phase I/II study evaluated the feasibility and efficacy of S-1,
leucovorin, oxaliplatin and gemcitabine (SLOG), a triplet regimen, for treating patients with …